Rebelo

Managing the transition to central bank digital currency

Retrieved on: 
Mercredi, février 14, 2024
Technical report, Regulation, Private sector, Aircraft, Interest, RTD, Policy, CES, Research Papers in Economics, A.2, The Economic Journal, RTK, International Settlement, F30, Next, A.6, Community business development corporation, A.7, UIP, American Economic Journal, National bank, Paper, Bank, Macroeconomics, Economy, Central bank, GSS, Capital, XF, Elasticity, Government, Competition, Credit, Social science, Volatility, Domestic, European, IH, Investment, A.13, SSRN, Intermediate, A.5, Section 2, AP, Probability, Review of Economic Dynamics, Foreign, Journal of Monetary Economics, Remuneration, Uncertainty, Medical classification, Bank of England, Shock, DF, Bank of Canada, ISSN, CIA, European Central Bank, Survival, RD, FH, KT, N B, Cuore, Monetary economics, Section 3, Welfare, Iteration, DSGE, Blessthefall, Reserve, Website, GBP, Calibration, RDC, Parameter, DCT, GDP, KF, Sokol, Rebelo, Figure, De Nederlandsche Bank, Parity, TFP, Depreciation, Total, BIS, Home, Section 4, Attitude, Acquisition, JEL, Cross, Household, FF, QT, Control, Swiss, Motion, ECB, M. A, GF, A.9, RT, Cattolica, Exercise, C.2, XH, Tax, Crowding, European Parliament, Literature, Reproduction, Political economy, Committee, Exp, E50, Uhlig, EUR, IID, Digital currency, Tourism, American Economic Review, Manuscript, AG, A.8, Research, F41, Friction, Public sector, PDF, U N, YH, Cryptocurrency
Key Points: 

    Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise

    Retrieved on: 
    Jeudi, juin 1, 2023
    Biotechnology, Pharmaceutical, Health, Clinical Trials, Molecule, Clinical pharmacology, Amgen, Drug development, Therapy, Senior, AXA, Head, Drug, MedImmune, BTD, Bristol Myers Squibb, MBA, Bayer, Lung cancer, SMT, Rebelo, Science, Novartis, Baynes, JD, Engineering, RAC, Merck, Shirin David, Pharmaceutical industry, EU, Hayward, Genmab, Eikon

    Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization.

    Key Points: 
    • Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization.
    • Eikon recently announced its development pipeline, which includes a number of acquired clinical and preclinical stage assets that complement its discovery-stage programs.
    • Harry Raftopoulos, M.D., Senior Vice President, Clinical Research Oncology –Raftopoulos joined from Bayer Pharmaceuticals, where he most recently served as Head of Late-Stage Oncology Clinical Development.
    • Based in the company’s New York City and Hayward locations, additional clinical development team members recently appointed include:

    Haverford Trust Adds OCIO Services

    Retrieved on: 
    Mardi, octobre 26, 2021
    Quality, View, Trust, Investment, VP, CIPM, CFA, CEO, Growth, Multimedia, Rebelo, Rittenhouse Square, UHNW, Financial services, Life insurance, Pension fund, Security (finance)

    "Now, under the helm of Haverford Trust, we will amplify our strengths and augment our collective services, creating a whole that is greater than the sum of our parts.

    Key Points: 
    • "Now, under the helm of Haverford Trust, we will amplify our strengths and augment our collective services, creating a whole that is greater than the sum of our parts.
    • We look forward to continuing to provide Haverford Trust and former Drexel Morgan Capital Advisers' clients with the highest quality wealth and investment management services."
    • As part of this combination, three Drexel Morgan Capital Advisers employees have joined Haverford Trust:
      Erich M. Hickey, CFA, becomes VP, Director of Manager Selection and OCIO Services.
    • *Including assets under management or consultation for The Haverford Trust Company and Haverford Financial Services as of 8/31/2021.

    DefinedCrowd's Founder and CEO Received by the President of Portugal

    Retrieved on: 
    Lundi, avril 19, 2021
    Countries, Grand Croix of the Légion d'honneur, Marcelo Rebelo de Sousa, Braga, President of Portugal, PORTUGAL, Rebelo

    b'SEATTLE, April 19, 2021 /PRNewswire/ --In the current context, His Excellency the President of Portugal received entrepreneur Dr. Daniela Braga during a hearing concerning the economic future of Portugal and the Recovery and Resilience Plan, which will be sent to Brussels by the end of the month.\n"I deeply admire the President of Portugal, Marcelo Rebelo de Sousa.

    Key Points: 
    • b'SEATTLE, April 19, 2021 /PRNewswire/ --In the current context, His Excellency the President of Portugal received entrepreneur Dr. Daniela Braga during a hearing concerning the economic future of Portugal and the Recovery and Resilience Plan, which will be sent to Brussels by the end of the month.\n"I deeply admire the President of Portugal, Marcelo Rebelo de Sousa.
    • It was a great honor to meet and talk with His Excellency, especially about a subject that\'s so close to my heart," said Dr. Braga after the hearing.
    • Regarding Portugal\'s economic and social future, Dr. Braga said: "With the world still reeling from the impact of a global pandemic, social and economic concerns are understandably at the top of every country\'s agenda.
    • "\nThe hearing took place last FridayApril 16at 3 p.m. GMT, via videoconference.\n'